Myriad Genetics, Inc. (0K3W.L)
USD 7.62
(4.89%)
USD 7.62
(4.89%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -112 Million USD | -311.76% |
| 2021 | -27.2 Million USD | 87.84% |
| 2020 | -223.7 Million USD | -4963.04% |
| 2019 | 4.6 Million USD | 0.0% |
| 2018 | 4.6 Million USD | -96.49% |
| 2017 | 131 Million USD | 500.92% |
| 2016 | 21.8 Million USD | -82.6% |
| 2015 | 125.3 Million USD | 56.23% |
| 2014 | 80.2 Million USD | -54.49% |
| 2013 | 176.22 Million USD | 19.77% |
| 2012 | 147.13 Million USD | 31.2% |
| 2011 | 112.15 Million USD | 11.36% |
| 2010 | 100.71 Million USD | -33.88% |
| 2009 | 152.3 Million USD | 80.0% |
| 2008 | 84.61 Million USD | 76.85% |
| 2007 | 47.84 Million USD | 236.85% |
| 2006 | -34.96 Million USD | 8.45% |
| 2005 | -38.18 Million USD | 4.47% |
| 2004 | -39.97 Million USD | 1.58% |
| 2003 | -40.62 Million USD | -63.63% |
| 2002 | -24.82 Million USD | -77.46% |
| 2001 | -13.98 Million USD | -94.99% |
| 2000 | -7.17 Million USD | 17.74% |
| 1999 | -8.72 Million USD | 12.78% |
| 1998 | -10 Million USD | -2.04% |
| 1997 | -9.8 Million USD | -6.52% |
| 1996 | -9.2 Million USD | -55.93% |
| 1995 | -5.9 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | -54.7 Million USD | -29.31% |
| 2023 Q3 | -61.3 Million USD | 47.2% |
| 2023 Q2 | -116.1 Million USD | -112.25% |
| 2022 Q4 | -42.3 Million USD | -20.51% |
| 2022 Q3 | -35.1 Million USD | -148.94% |
| 2022 Q2 | -14.1 Million USD | 31.22% |
| 2022 Q1 | -20.5 Million USD | -169.74% |
| 2022 FY | -112 Million USD | -311.76% |
| 2021 Q4 | -7.6 Million USD | -130.89% |
| 2021 Q2 | -4.7 Million USD | 88.1% |
| 2021 Q1 | -39.5 Million USD | 10.63% |
| 2021 FY | -27.2 Million USD | 87.84% |
| 2021 Q3 | 24.6 Million USD | 623.4% |
| 2020 Q3 | -15.2 Million USD | 72.56% |
| 2020 FY | -223.7 Million USD | -4963.04% |
| 2020 Q2 | -55.4 Million USD | 51.91% |
| 2020 Q1 | -115.2 Million USD | -1287.95% |
| 2020 Q4 | -44.2 Million USD | -190.79% |
| 2019 Q1 | 6.9 Million USD | 165.38% |
| 2019 Q2 | -4.2 Million USD | -160.87% |
| 2019 Q3 | -20.6 Million USD | -390.48% |
| 2019 Q4 | -8.3 Million USD | 59.71% |
| 2019 FY | 4.6 Million USD | 0.0% |
| 2018 Q2 | 13.1 Million USD | 14.91% |
| 2018 Q4 | 2.6 Million USD | 471.43% |
| 2018 FY | 4.6 Million USD | -96.49% |
| 2018 Q1 | 11.4 Million USD | -64.49% |
| 2018 Q3 | -700 Thousand USD | -105.34% |
| 2017 Q1 | 4.2 Million USD | -28.81% |
| 2017 Q4 | 32.1 Million USD | -60.42% |
| 2017 FY | 131 Million USD | 500.92% |
| 2017 Q3 | 81.1 Million USD | 528.68% |
| 2017 Q2 | 12.9 Million USD | 207.14% |
| 2016 Q4 | 5.9 Million USD | 591.67% |
| 2016 Q2 | 23.4 Million USD | -28.22% |
| 2016 Q1 | 32.6 Million USD | 7.59% |
| 2016 FY | 21.8 Million USD | -82.6% |
| 2016 Q3 | -1.2 Million USD | -105.13% |
| 2015 Q3 | 26.6 Million USD | 42.25% |
| 2015 FY | 125.3 Million USD | 56.23% |
| 2015 Q1 | 21.47 Million USD | -10.64% |
| 2015 Q2 | 18.7 Million USD | -12.92% |
| 2015 Q4 | 30.3 Million USD | 13.91% |
| 2014 Q3 | 15.98 Million USD | -52.48% |
| 2014 Q4 | 24.03 Million USD | 50.36% |
| 2014 FY | 80.2 Million USD | -54.49% |
| 2014 Q1 | 36.77 Million USD | -26.99% |
| 2014 Q2 | 33.62 Million USD | -8.54% |
| 2013 Q2 | 44.07 Million USD | 16.32% |
| 2013 Q1 | 37.89 Million USD | 8.15% |
| 2013 FY | 176.22 Million USD | 19.77% |
| 2013 Q4 | 50.36 Million USD | -9.2% |
| 2013 Q3 | 55.46 Million USD | 25.84% |
| 2012 FY | 147.13 Million USD | 31.2% |
| 2012 Q1 | 29.61 Million USD | 4.66% |
| 2012 Q4 | 35.03 Million USD | 16.26% |
| 2012 Q3 | 30.13 Million USD | 3.41% |
| 2012 Q2 | 29.14 Million USD | -1.6% |
| 2011 Q2 | 26.04 Million USD | -6.8% |
| 2011 Q4 | 28.29 Million USD | 12.74% |
| 2011 FY | 112.15 Million USD | 11.36% |
| 2011 Q1 | 27.94 Million USD | 15.5% |
| 2011 Q3 | 25.09 Million USD | -3.61% |
| 2010 FY | 100.71 Million USD | -33.88% |
| 2010 Q3 | 22.53 Million USD | -57.68% |
| 2010 Q2 | 53.25 Million USD | 60.15% |
| 2010 Q1 | 33.25 Million USD | -5.96% |
| 2010 Q4 | 24.19 Million USD | 7.33% |
| 2009 Q1 | 25.31 Million USD | 19.41% |
| 2009 Q4 | 35.35 Million USD | 16.15% |
| 2009 Q3 | 30.44 Million USD | 28.77% |
| 2009 Q2 | 23.64 Million USD | -6.63% |
| 2009 FY | 152.3 Million USD | 80.0% |
| 2008 Q1 | -4.63 Million USD | 8.6% |
| 2008 FY | 84.61 Million USD | 76.85% |
| 2008 Q4 | 21.2 Million USD | 46.69% |
| 2008 Q3 | 14.45 Million USD | -77.95% |
| 2008 Q2 | 65.54 Million USD | 1515.27% |
| 2007 Q3 | -7.99 Million USD | -2.5% |
| 2007 Q2 | -7.8 Million USD | -31.45% |
| 2007 Q1 | -5.93 Million USD | 32.5% |
| 2007 FY | 47.84 Million USD | 236.85% |
| 2007 Q4 | -5.06 Million USD | 36.65% |
| 2006 Q2 | -11.42 Million USD | -19.36% |
| 2006 Q1 | -9.57 Million USD | -20.36% |
| 2006 FY | -34.96 Million USD | 8.45% |
| 2006 Q4 | -8.79 Million USD | 29.21% |
| 2006 Q3 | -12.42 Million USD | -8.76% |
| 2005 Q4 | -7.95 Million USD | 13.96% |
| 2005 FY | -38.18 Million USD | 4.47% |
| 2005 Q2 | -9.95 Million USD | 0.34% |
| 2005 Q1 | -9.98 Million USD | 0.62% |
| 2005 Q3 | -9.24 Million USD | 7.13% |
| 2004 Q2 | -10.46 Million USD | 2.2% |
| 2004 Q1 | -10.69 Million USD | -8.54% |
| 2004 Q3 | -9.99 Million USD | 4.48% |
| 2004 Q4 | -10.04 Million USD | -0.56% |
| 2004 FY | -39.97 Million USD | 1.58% |
| 2003 Q1 | -5.53 Million USD | 19.73% |
| 2003 Q2 | -7.08 Million USD | -27.95% |
| 2003 Q3 | -9.6 Million USD | -35.7% |
| 2003 FY | -40.62 Million USD | -63.63% |
| 2003 Q4 | -9.85 Million USD | -2.55% |
| 2002 Q4 | -6.89 Million USD | -29.68% |
| 2002 FY | -24.82 Million USD | -77.46% |
| 2002 Q3 | -5.31 Million USD | 22.37% |
| 2002 Q2 | -6.84 Million USD | -95.87% |
| 2002 Q1 | -3.49 Million USD | -42.15% |
| 2001 Q4 | -2.45 Million USD | -107.55% |
| 2001 FY | -13.98 Million USD | -94.99% |
| 2001 Q1 | -1.72 Million USD | -45.28% |
| 2001 Q2 | -2.18 Million USD | -26.53% |
| 2001 Q3 | -1.18 Million USD | 45.8% |
| 2000 FY | -7.17 Million USD | 17.74% |
| 2000 Q4 | -1.18 Million USD | 42.55% |
| 2000 Q1 | -2.09 Million USD | -10.0% |
| 2000 Q2 | -2.56 Million USD | -22.68% |
| 2000 Q3 | -2.07 Million USD | 19.25% |
| 1999 Q2 | -2.3 Million USD | -4.55% |
| 1999 Q1 | -2.2 Million USD | 24.14% |
| 1999 FY | -8.72 Million USD | 12.78% |
| 1999 Q4 | -1.9 Million USD | 13.64% |
| 1999 Q3 | -2.2 Million USD | 4.35% |
| 1998 Q4 | -2.9 Million USD | -7.41% |
| 1998 FY | -10 Million USD | -2.04% |
| 1998 Q1 | -2.6 Million USD | -13.04% |
| 1998 Q2 | -3.1 Million USD | -19.23% |
| 1998 Q3 | -2.7 Million USD | 12.9% |
| 1997 Q1 | -3.2 Million USD | 8.57% |
| 1997 Q2 | 300 Thousand USD | 109.38% |
| 1997 Q3 | -1.8 Million USD | -700.0% |
| 1997 FY | -9.8 Million USD | -6.52% |
| 1997 Q4 | -2.3 Million USD | -27.78% |
| 1996 Q3 | -2.8 Million USD | -47.37% |
| 1996 FY | -9.2 Million USD | -55.93% |
| 1996 Q1 | -1.8 Million USD | -157.14% |
| 1996 Q4 | -3.5 Million USD | -25.0% |
| 1996 Q2 | -1.9 Million USD | -5.56% |
| 1995 Q4 | -700 Thousand USD | 56.25% |
| 1995 FY | -5.9 Million USD | 0.0% |
| 1995 Q3 | -1.6 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| uniQure N.V. | -308.47 Million USD | 63.693% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -106.688% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -26.581% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 68.19% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 59.439% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 5.496% |
| Imunon, Inc. | -19.51 Million USD | -473.918% |
| Dynavax Technologies Corporation | -6.38 Million USD | -1653.013% |
| Editas Medicine, Inc. | -153.21 Million USD | 26.902% |
| FibroGen, Inc. | -284.23 Million USD | 60.596% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 74.777% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -165.409% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 144.854% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 79.104% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 8610.638% |
| Verastem, Inc. | -87.36 Million USD | -28.195% |
| Zoetis Inc. | 2.34 Billion USD | 104.778% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 103.094% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 56.561% |
| Homology Medicines, Inc. | -53.74 Million USD | -108.399% |
| Nektar Therapeutics | -276.05 Million USD | 59.429% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -30.392% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -180.983% |
| Perrigo Company plc | -12.7 Million USD | -781.89% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 46.475% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 98.703% |
| Illumina, Inc. | -1.16 Billion USD | 90.353% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 101.868% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 108.247% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -1.303% |
| Waters Corporation | 642.23 Million USD | 117.439% |
| Biogen Inc. | 1.16 Billion USD | 109.646% |
| Evolus, Inc. | -61.68 Million USD | -81.568% |
| Adicet Bio, Inc. | -142.65 Million USD | 21.491% |
| bluebird bio, Inc. | -211.91 Million USD | 47.148% |
| Geron Corporation | -184.12 Million USD | 39.172% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 74.559% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 26.114% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 76.724% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 114.199% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -151.102% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 166.808% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 102.833% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 109.032% |
| OPKO Health, Inc. | -188.86 Million USD | 40.698% |
| Exelixis, Inc. | 207.76 Million USD | 153.907% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 205.521% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -135.765% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 53.185% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 69.423% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 139.774% |
| Blueprint Medicines Corporation | -506.98 Million USD | 77.909% |
| Insmed Incorporated | -749.56 Million USD | 85.058% |
| TG Therapeutics, Inc. | 12.67 Million USD | 983.838% |
| Incyte Corporation | 597.59 Million USD | 118.742% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 85.273% |